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Background: Cardiovascular risk factors, including diabetes mellitus may attenuate the cardioprotection by
postconditioning. This study aimed to investigate the cardioprotective effect of ischemic-postconditioning (IPostC)
against ischemia/reperfusion injury in normal and chronically type-1 diabetic rats and the effect of mitochondrial
permeability transition pore (mPTP) inhibition in this field.
Methods: Diabetes was induced by a single intra-peritoneal injection of streptozotocin (50 mg/kg) in Wistar male
rats (250-300 g). After 8 weeks, the hearts of control and diabetic animals were isolated and mounted on a
constant-pressure Langendorff apparatus. All hearts were subjected to 30 min regional ischemia followed by 45 min
reperfusion (by occluding and re-opening of LAD coronary artery, respectively). At the end of ischemia, the hearts
received IPostC, cyclosporine-A, or both or none of them. Myocardial creatine-kinase (CK) release as an index of
tissue injury was measured spectrophotometery in coronary effluent in reperfusion phase. Infarct size was identified
by triphenyltetrazolium chloride staining. Heart rate, left ventricular end-diastolic pressure (LVEDP), LV systolic
pressure (LVSP), rate-pressure product (RPP) and coronary flow were recorded throughout the experiment.
Results: IPostC, applied at the onset of reperfusion, failed to improve myocardial LVEDP and RPP, or reduce tissue
damage indicated by infarct size and CK release in diabetic hearts, while it significantly recovered these parameters
toward the pre-ischemic values in control hearts (P < 0.05). In contrast, with simultaneous inhibition of mPTP using
cyclosporine-A, the cardioprotective effects of IPostC on myocardial hemodynamics, infarct size and CK release were
significantly restored in diabetic hearts (P < 0.05).
Conclusions: The loss of cardioprotection by IPostC in diabetic state can be overcome by increasing the potency
of protective IPostC through its co-application with mPTP inhibition.
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Myocardial reperfusion injury is a condition in which re-
storing the blood supply to the tissue after a long period of
ischemia or lack of oxygen further damage the myocar-
dium and leads to myocardial infarction (MI) [1]. Several
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unless otherwise stated.and postconditioning have been examined in experimental
animals and humans, with promising results [2-4]. Ische-
mic postconditioning (IPostC) is a strategy by which
the repetitive very short episodes of ischemia and re-
perfusion (I/R) applied at the onset of reperfusion con-
fers significant cardioprotective effects and limit MI [4].
Unfortunately, the majority of the studies investigating
the protective effects of IPostC have been performed
in models of healthy animals without underlying risk
factors and comorbidities, including diabetes mellitus.
This is in contrast to human populations with ischemic
heart disease (IHD) who also have other comorbiditiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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strategies [5-7].
Diabetes mellitus is a metabolic disorder characterized
by hyperglycemia and insufficient secretion or action
of endogenous insulin in the body [8] and is associ-
ated with a higher risk of IHD including MI. Diabetic
mellitus might affect the myocardium in diabetic pa-
tients causing changes at the cellular level, which, in turn,
lead to a wide range of structural and biochemical abnor-
malities eventually leading to systolic and diastolic dys-
function [9].
Currently, there is little knowledge about the inter-
action of chronic diabetes with cardioprotective effect of
IPostC and the mechanisms of this interaction are also
not understood completely. One of the critical determi-
nants of the reperfusion injury is the mitochondrial per-
meability transition pore (mPTP) which opens during
reperfusion injury due to oxidative stress, Ca2+overload,
decreased ATP levels, and increased matrix pH [10].
The mPTP has also been linked to the pathophysiology
of diabetes-induced alterations in cellular mechanisms
[11]. To our knowledge, mPTP play a crucial role in post-
conditioning. IPostC has been suggested to close this non-
selective ion channel via involving a variety of intracellular
mediators and thereby confer a cardioprotection [12].
Cyclosporine-A (CsA) is an immunosuppressive agent
which also inhibits the mPTP opening at reperfusion
and previous studies have revealed that it is possible
to protect the heart against I/R injury by CsA administra-
tion at the onset of reperfusion [10,12], however, it has not
been feasible in diabetic hearts as reported by some studies
[13] and restoring the protection in diabetes is of clinically
important.
Therefore, because of the clinical importance of the
interaction of chronic diabetes with cardiovascular diseases
and cardioprotective mechanisms of IPostC and due to the
lack of enough information in this subject, this study inves-
tigated the cardioprotective effect of IPostC against I/R
injury in normal and chronically streptozotocin-induced
diabetic rats and the effect of simultaneous inhibition of
mPTP in this field.
Materials and methods
Animals
Male Wistar rats (250–300 g body weight) were used
in this study and had free access to food and water
at all times before the start of the experiments. They
were housed in laboratory room with a 12-h dark
and 12-h light cycle. This study was performed in
accordance with the Guide for the Care and Use of
Laboratory Animals published by the US National
Institutes of Health (NIH publication No 85–23, re-
vised 1996) and was approved by the local Animal Care
and Ethics Committee.Induction of diabetes
Diabetes was induced by a single intra-peritoneal injection
of streptozotocin (50 mg/kg body weight; Sigma-Aldrich,
Germany) in diabetic groups. Development of the diabetes
was confirmed 72 h later by measuring blood glucose
levels using a glucometer device through the sampling
of blood with small scratching of tail of rats. The ani-
mals with blood glucose levels higher than 300 mg/dl
were considered as diabetic [14,15]. After 8 weeks of
the disease, the diabetic animals as well as the age-
matched controls were sacrificed and all experiments
were performed in isolated perfused hearts.
Surgical preparation, isolated heart perfusion and
hemodynamics measurements
Surgical preparation was performed as described previ-
ously [16,17]. All animals were heparinized (500 IU)
and anesthetized with a mixture of ketamine (60 mg/kg)
and xylosine (10 mg/kg) intra-peritoneally. The hearts
were rapidly excised, then mounted on the Langendorff
perfusion apparatus and retrogradely perfused via the
aorta with a Krebs–Henseleit (K-H) solution (in mM/l:
NaCl 118; KCl 4.7; CaCl2 2.5; MgSO4. 1.2; NaHCO3 25;
KH2PO4 1.2; Glucose 11.1; all materials from Merck,
Germany) at a constant perfusion pressure of 75 mmHg
and pH 7.4. The perfusion solution was gassed with a
mixture of 95% O2, 5% CO2 at 37°C. A water-filled latex
balloon was inserted into the left ventricle through an
incision in the left atrium. The balloon volume was
adjusted to produce 5–10 mmHg of end-diastolic pres-
sure at the onset of experimen in all experimental
groups. Hemodynamic data from the balloon were digi-
tized and continuously recorded by a data acquisition
system (PowerLab; ADInstruments, Australia), displayed
on a monitor and analyzed using Chart 7.3 for windows
Software. The heart rate (HR), left ventricular end dia-
stolic pressure (LVEDP), left ventricular systolic pres-
sure (LVSP), and rate-pressure product (RPP = LVSP ×HR)
were recorded. The coronary flow (CF) was measured
by timed-collection of coronary effluent in certain time
points.
Induction of regional ischemia and reperfusion
At the onset of experiment, a 5–0 silk thread was placed
around the left anterior descending (LAD) coronary
artery, close to its origin. After stabilization period
(15 min), all hearts were subjected to regional ischemia
for 30 min followed by reperfusion for 45 min. Regional
ischemia and reperfusion were induced by occluding and
re-opening of LAD, respectively. An immediate fall in
coronary flow at the onset of index ischemia (to about
30-40% of its baseline value) and its recovery upon reper-
fusion served as evidences of effective coronary occlusion
and reperfusion [18]. Ischemic postconditioning (IPostC)
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and ischemia (3 cycles of 30s R/I), respectively, immedi-
ately at the onset of reperfusion.
Exclusion criteria
During the 8-week of diabetes induction and before the
starting the experiment on the Langendorff setting, the
diabetic animals with blood glucose levels lower than
300 mg/dl were excluded from the study. Moreover, in
the Langendorff setting, the isolated hearts were ex-
cluded from the experiment if their baseline LVDP was
lower than 70 mmHg in control rats or if they showed
severe arrhythmias or if there were no effective coronary
occlusion and reperfusion.
Experimental protocols
The animals were divided into eight groups (n = 6 each)
as following:
1) Control (C); in which after surgical preparation and
stabilization period, the isolated hearts of non-diabetic
animals were subjected to 30 min ischemia and 45 min
reperfusion.
2) Control with ischemic postconditioning (C + IPostC);
in which the condition was similar to the control
group except that at the onset of reperfusion, the
hearts were received 3 cycles of 30s R/I.
3) Control with cyclosporine-A (C + CsA); in which
the condition was similar to the control group
except that 5 min before the onset of reperfusion
up to 10 min of reperfusion, the hearts were
perfused with a K-H solution containing
0.01 mM CsA.
4) Control with ischemic postconditioning plus
cyclosporine-A (C + IPostC + CsA); in which the
condition was similar to the control group except
that 5 min before the onset of reperfusion up to
10 min of reperfusion, the hearts were perfused
with a K-H solution containing CsA, and at the
onset of reperfusion, they were received 3 cycles
of 30s R/I.
5) Diabetic (D); in which after surgical preparation and
stabilization period, the isolated hearts of 8-week
diabetic animals were subjected to 30 min ischemia
and 45 min reperfusion.
6) Diabetic with ischemic postconditioning (D + IPostC);
in which the condition was similar to the diabetic
group except that at the onset of reperfusion, the
hearts were received 3 cycles of 30s R/I.
7) Diabetic with cyclosporine-A (D + CsA); in which
the condition was similar to the diabetic group except
that 5 min before the onset of reperfusion up to
10 min of reperfusion, the hearts were perfused
with a K-H solution containing CsA.8) Diabetics with ischemic postconditioning plus
cyclosporine A (D + IPostC + CsA); in which the
condition was similar to the diabetic group except
that 5 min before the onset of reperfusion up to
10 min of reperfusion, the hearts were perfused
with a K-H solution containing CsA, and at the
onset of reperfusion, they were received 3 cycles
of 30s R/I.
Measurement of creatine kinase
The coronary effluent was collected for 10 min after ini-
tiation of reperfusion for measuring the activity of creat-
ine kinase (CK) as an index for tissue injury. The CK
activity in the coronary effluent was measured by an
automatic biochemistry analyzer using a commercially
available kit according to the manufacturer’s instruc-
tions, and the values was normalized to whole volumes
of the effluent in each heart. The absorbance of the solu-
tion was detected at 340 nm by spectrophotometery.
The results were reported in U/L.
Measurement of infarct size
In another series of experiment with a similar grouping
with a reperfusion period of 60 minutes, infarct sizes
were identified as described previously. At the end of
the experiment, the LAD coronary artery was then re-
occluded at the same site and 3 to 4 mL of 0.25% Evans
blue dye was infused via the aortic root into the coron-
ary system. These identify the area at risk as unstained
and non-ischemic part of the myocardium as blue. The
heart was then frozen, cut into thin slices (2 mm) from
the apex to the base and incubated (for 10 to 15 minutes
at 37°C) in buffered 1% 2,3,5-triphenylte-trazolium chlor-
ide (TTC) to identify viable myocardium as red stained
while necrotic (infarct) tissue remains pale gray. The Left
ventricular, risk zones and infarcted areas were deter-
mined using a computerized planimetry (Summa Sketch
III, SummaGraphics, USA by one observer blinded to the
study group. The infarct sizes were expressed as a percent-
age of the left ventricular risk zones and the volumes were
calculated by multiplying the areas by slice thickness and
summing them for each heart.
Statistical analysis
All values were expressed as means ± SEM. The differences
between groups were analyzed using repeated measures
ANOVA with bonferroni test or One-way ANOVA
followed by Tukey's post hoc test. Differences were consid-
ered statistically significant when P < 0.05.
Results
Baseline parameters
The baseline hemodynamics recorded before the induc-
tion of ischemia in experimental subgroups are shown in
Table 1 Baseline values of hemodynamic parameters in non-diabetic control and diabetic sub-groups
Group HR (beat/min) CF (ml/min) LVEDP (mmHg) LVSP (mmHg) RPP (1/1000)
C 259 ± 12 10.6 ± 0.9 7.4 ± 0.7 94 ± 6 25.2 ± 0.80
C + IPostC 272 ± 11 11.0 ± 0.6 7.1 ± 0.7 97 ± 5 26.5 ± 0.73
C + CsA 277 ± 14 12.8 ± 1.4 6.7 ± 0.6 99 ± 6 27.7 ± 0.92
C + IPostC + CsA 274 ± 26 11.6 ± 0.5 7.3 ± 1.1 102 ± 7 28.0 ± 1.47
D 198 ± 13* 7.7 ± 0.7* 8.5 ± 0.8 78 ± 8* 15.7 ± 0.93*
D + IPostC 192 ± 16* 9.0 ± 0.8* 7.4 ± 0.8 75 ± 8* 14.6 ± 1.41*
D + CsA 202 ± 12* 9.8 ± 1.2* 8.0 ± 0.6 78 ± 6* 15.0 ± 0.65*
D + IPostC + CsA 224 ± 18* 9.5 ± 0.9* 7.8 ± 0.9 73 ± 7* 16.6 ± 1.38*
*P < 0.05 as compared with control groups. Abbreviation: "C" control, "C + IPostC" control with ischemic postconditioning, "C + CsA" control with cyclosporine-A,
"C + IPostC + CsA" control with ischemic postconditioning plus cyclosporine-A, "D" diabetic, "D + IPostC" diabetic with ischemic postconditioning, "D + CsA" diabetic
with cyclosporine-A, "D + IPostC + CsA" diabetics with ischemic postconditioning plus cyclosporine-A. HR heart rate, CF coronary flow, LVEDP left ventricular end
diastolic pressure, LVSP LV systolic pressure, and RPP rate-pressure product.
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chronic disease in the present study, the diabetic animals
showed a marked myocardial dysfunction and cardiomy-
opathy, as revealed by significantly reduced HR, CF,
LVSP and RPP in diabetic animals as compared to those
of control animals (P < 0.05). Although there was no sig-


































Figure 1 CK activity in coronary effluent of non-diabetic control (top)
group D (bottom).control subgroups or within diabetic subgroups, these
baseline parameters were significantly lower in all diabetics
than controls (Table 1).
CK activity
The levels of CK release into the coronary effluent of both





and diabetic (bottom) hearts. *P < 0.01 vs. group C (top) or vs.
Figure 2 Infarct sizes (in percentage of I/R group) in non-diabetic
control (gray bars) and diabetic (dark bars) hearts. *P< 0.05 vs.
corresponding I/R control group; and #P< 0.01 vs. corresponding I/R
diabetic group.
Figure 3 The alterations of the left ventricular end diastolic pressure
subgroups throughout the ischemia (Isch) and reperfusion (Rep) time
which the values have recorded. #P < 0.05 difference between C + IPostC a
difference between C + IPostC + CsA and C (top); or between D + IPostC +
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cyclosporine-A (CsA), alone or in combination with each
other (IPostC + CsA) significantly reduced CK levels as
compared to non-treated control hearts (C) (P < 0.01).
However, in diabetic hearts, only the combination ther-
apy (IPostC + CsA) could significantly reduced the CK
levels as compared to non-treated diabetic hearts (D)
(P < 0.01); the CK reducing effects of IPostC alone or
CsA alone were not significant in comparison with dia-
betic group (Figure 1).
Infarct size
According to the results of Evans Blue staining, 30 min
occluding of LAD produced similar risk zones or ex-
tent of ischemic tissue (which indicates the degree of
ischemic stimulus) in both control and diabetic hearts(LVEDP; in mmHg) in control (C; top) and diabetic (D; bottom)
. The numbers in horizontal axis (time point) represent the minutes at
nd C; †P < 0.05 difference between C + CsA and C; and *P < 0.05
CsA and D (bottom).
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zones between all groups of control and diabetic animals
(averaged 43.78 ± 3.9% of LV volumes in controls vs. av-
eraged 47.31 ± 3.7% of LV volumes in diabetics). On the
other hand, thirty minutes ischemia and sixty minutes
reperfusion led to the development of 41.2 ± 2.9% in-
farct size in control hearts vs. 39.3 ± 3.1% in diabetic
hearts. Both alone treatment of IPostC or CsA signifi-
cantly reduced the infarct size of non-diabetic control
hearts by 33% and by 42%, respectively (P < 0.05). How-
ever, neither IPostC nor CsA significantly reduced the
infarct size in the diabetic rats. Furthermore, in non-
diabetic hearts, combined administration of IPostC with
CsA had a greater and significant infarct reducing effect
(by 54%) as compared with those of control untreated-
hearts (P < 0.01). Although IPostC alone could not alter
the infarct size in diabetic rats, combination of CsA
and IPostC provided a significant infarct reducing effect
(by 46%) in diabetic groups (P < 0.01) (Figure 2).Figure 4 The alterations of the myocardial rate-pressure product (RP
subgroups throughout the ischemia (Isch) and reperfusion (Rep) tim
difference between C + CsA and C; and *P < 0.05 difference between C +
D (bottom).LVEDP alterations during I/R
Administration of IPostC or CsA, alone or in combin-
ation, significantly prevented the reperfusion-induced
increase in LVEDP in control non-diabetic animals
(P < 0.05). None of IPostC or CsA alone could reduce the
LVEDP during the reperfusion phase in diabetic animals.
However, concomitant administration of both IPostC
and CsA completely prevented the increase in LVEDP in
diabetic hearts (P < 0.05) (Figure 3).
RPP alterations during I/R
IPostC and CsA in non-diabetic control animals signifi-
cantly improved the RPP, as an index for cardiac work, at
some time points during reperfusion (P < 0.05) (Figure 4).
In contrast, both of them failed to restore the myocardial
RPP in diabetic rats. Nevertheless, administration of CsA
in postconditioned diabetic hearts could significantly re-
turn the RPP during reperfusion toward the pre-ischemic
baseline values, similar to those in non-diabetic controlP;% of baseline) in control (C; top) and diabetic (D; bottom)
e. #P < 0.05 difference between C + IPostC and C; †P < 0.05
IPostC + CsA and C (top); or between D + IPostC + CsA and
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no significant differences in RPP between three sub-
groups of IPostC, CsA and IPostC + CsA in control ani-
mals (Figure 4, top).
HR alterations during I/R
Diabetic hearts had lower HR than control animals
during the experiment. In these hearts, the HR was
reduced by 30 min ischemia and recovered through
reperfusion. During I/R time, HR alterations in all groups
were not statistically significant throughout the ex-
periment. Additionally, there was no significant dif-
ference of this parameter among groups in ischemic and
reperfusion phases of the control and diabetic groups
(Figure 5).
CF alterations during I/R
Regional ischemia induced by occluding LAD reduced the
coronary flow both in control and diabetic hearts. Although
IPostC and/or CsA tended to increase the CF in reperfu-
sion phase, there was no statistically significant difference
in the CF in either diabetic or non-diabetic control
subgroups throughout the experiment (Figure 6).Figure 5 The alterations of the heart rate (HR; in beats per minutes, b
throughout the ischemia (Isch) and reperfusion (Rep) time.Discussion
This study indicated that IPostC as a potent cardiopro-
tective stimulus did not exert its protective effect in
diabetic hearts. However, if the mPTP was inhibited sim-
ultaneously, the protection by IPostC might be restored
in these diseased hearts. Because diabetes is the most
common comorbidity of acute myocardial infarction in
clinics and the prognosis of acute myocardial infarction
with diabetes is not very good, this investigation has
focused the postconditioning's protective effects on
normal and diabetic myocardium.
IPostC is a clinically relevant and feasible strategy which
protects the ischemic heart via several ways. The main
pathways that have been suggested to contribute to IPostC
protection are including Reperfusion Injury Salvage Ki-
nases (RISK) pathway which involves the kinases PI3K/
Akt and ERK1/2, and Survivor Activating Factor Enhance-
ment (SAFE) pathway which acts through the activation of
tumor necrosis factor-α, and JAK/STAT [4,16,19]. All
these pathways which some of them is impaired in dia-
betic states [20], converge on the mitochondria via the
modulation of several kinases such as glycogen synthase
kinase-3β, Bax/Bad and the ε isoform of protein kinase Cpm) in control (C; top) and diabetic (D; bottom) subgroups
Figure 6 The alterations of the coronary flow (CF; in ml/min) in control (C; top) and diabetic (D; bottom) subgroups throughout the
ischemia (Isch) and reperfusion (Rep) time.
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cardioprotection are inhibition of mPTP and/or opening
of mitochondrial ATP-sensitive K+ channels [4,21,22].
mPTP remains closed during myocardial ischemia but
opens due to Ca2+ overload and excessive production of
reactive oxygen species during the onset of reperfusion
which in turn, leads to disturbance in mitochondrial in-
tegrity and its function [22]. Long-lasting mPTP opening
is followed by profound alterations of cellular bioener-
getics that are considered irreversible [19]. Opening of
the mPTP results in collapse of the mitochondrial mem-
brane potential, and uncoupling of the respiratory chain.
In addition, pore opening leads to an influx of solutes
and water that causes mitochondrial matrix swelling and
loss of critical electrochemical gradients. In this condi-
tion, the mitochondrial F1/FO ATP synthase, which it
interacts with several mPTP regulators, actively hydro-
lyzes rather than synthesizes ATP, leading to inevitable
cell death [19,23,24]. This is rapidly followed by ATP and
NAD+ depletion and the greater increased mitochondrial
volume which can ultimately rupture the outer membrane
leading to release of inner membrane space contents suchas proapoptotic factors, including cytochrome-c and thus
also inhibits electron flow through the electron transport
chain. These events are thought to be detrimental for myo-
cardial reperfusion injury [10,21,22,24]. Among other com-
ponents of mPTP, the involvement of F1/FO ATP synthase
especially its c subunit in mPTP formation has recently
been demonstrated and this has attained great interest in
the field of myocardial I/R injury, because it links the mito-
chondrial function to its bioenergetics [23-26]. Recent
evidences suggest that an uncoupling channel within
the c-subunit ring of the F1/FO ATP synthase is the
mitochondrial permeability transition pore [25].
In this study, IPostC alone could elicit protection in
normal hearts and co-administration of CsA, as a potent
mPTP blocker, with IPostC could not increase further
the effect of IPostC in these hearts without underlying
risk factor. This finding indicates that IPostC and CsA
have no significant additive effect on each other in con-
trol animals, and the cardioprotection is achieved by
enough inhibition of mPTP. However, in 8-week diabetic
animals, we were unable to show any protection by
IPostC. That is, IPostC in these animals neither restored
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RPP) toward baseline value nor reduced the infarct size
and CK levels as compared to corresponding controls.
Furthermore, CsA was also unable to induce such pro-
tective effects in diabetic hearts. There is no enough
report about interaction of chronic diabetes with post-
conditioning; and our study was in this context. Wagner
et al. [27] showed that IPostC fails to reduce infarct size
in transgenic rats with metabolic syndrome. In addition,
Przyklenk et al. [28] have reported that the diabetes abol-
ishes the cardioprotection by postconditioning. However,
the duration of type 1 diabetes in their study was 2 weeks
which correlates with the acute phase of the disease
and does not agree with chronic models. It is well-
documented now that early and acute (four-week or
less) and chronic (eight-week) phases of the diabetes re-
spond differently to I/R insults and likely to protective in-
terventions [6]. According to our results, the effects of
postconditioning are abolished in ischemic hearts accom-
panied with underlying chronic diabetes. Nevertheless,
restoration of protection to the ischemic hearts of diabetic
patients is clinically important.
We showed in the present study that the protection of
diabetic hearts against I/R injury is afforded by concomi-
tant application of IPostC and CsA, which each of them
separately produced cardioprotection only in healthy but
not in diabetic animals. According to these findings, it
seems that the effectiveness of IPostC in the diabetic
hearts is likely not strong as enough as the normal state
to activate endogenous cardioprotective pathways in an
effective way. After bringing CsA into play, however, the
effects of IPostC and CsA are added on each other, and
their final cardioprotective effects are enhanced. During
diabetes, there is a set of sub-cellular, hemodynamic and
metabolic abnormalities, each may attenuate or impede
the cardioprotective route of IPostC [9,29]. For example,
greater oxidative stress and hyperglycemia can block the
stimulatory effect of IPostC on different protective pro-
tein kinases or block the inhibitory effect of CsA and
IPostC on mPTP. Therefore, the lack of cardioprotection
in diabetic myocardium may be attributable, partly, to
these abnormalities and alterations. Therefore, further
research is needed to clarify the exact mechanisms of
diabetes-induced loss of cardioprotection.
In conclusion, IPostC alone or CsA alone could not
protect the diabetic myocardium against I/R injury.
However, by increasing the potency of protective stimulus
through co-application of two stimuli (IPostC plus CsA)
can overcome the loss of protection in diabetic state. The
loss of cardioprotection in diabetic heart can be partly re-
duced by targeting and sufficient inhibiting the mPTP.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
MM and RB made contributions to conception and design of study; SF and
MN helped in both data acquisition and statistical analysis and drafted the
manuscript. RB and MA involved in data acquisition and wrote and revised
the manuscript critically for important content. NA and BB reviewed and
edited the manuscript draft. All authors read and approved the final manuscript.
Acknowledgment
This work was supported by a grant from Drug Applied Research Center,
and Biotechnology Research Center, Tabriz University of Medical Sciences,
Tabriz-Iran.
Author details
1Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz,
Iran. 2Biotechnology Research Center, Tabriz University of Medical Sciences,
Tabriz, Iran. 3Department of Physiology, Faculty of Medicine, Tabriz University
of Medical Sciences, Tabriz, Iran. 4Immunology Research Center, Tabriz
University of Medical Sciences, Tabriz, Iran.
Received: 15 February 2014 Accepted: 21 October 2014
References
1. Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med
2007, 357:1121–1135.
2. Zaugg M, Schaub MC: Signaling and cellular mechanisms in cardiac
protection by ischemic and pharmacological preconditioning. J Musc Res
Cell Motil 2003, 24:219–249.
3. Murphy E, Steenbergen C: Mechanisms underlying acute protection from
cardiac ischemia-reperfusion injury. Physiol Rev 2008, 88:581–609.
4. Hausenloy DJ, Yellon DM: Preconditioning and postconditioning: united
at reperfusion. Pharmacol Ther 2007, 116:173–191.
5. Lemoine S, Puddu PE, Durand CL, Babatasi G, Ivascau C, Massett M, Gérard JL,
Hanouz JL: Signaling pathways involved in postconditioning-induced
cardioprotection of human myocardium, in vitro. Exp Biol Med 2010,
235(6):678–776.
6. Ravingerova T, Adameova A, Matejíkova J, Kelly T, Nemcekova M, Kucharska J:
Subcellular mechanisms of adaptation in the diabetic myocardium:
relevance to ischemic preconditioning in the nondiseased heart. Exp Clin
Cardiol 2010, 15(4):68–76.
7. Yadav HN, Singh M, Sharma PL: Modulation of the cardioprotective effect
of ischemic preconditioning in hyperlipidaemic rat heart. Eur J Pharmacol
2010, 643:78–83.
8. Maritim AC, Sanders RA, Watkins JB: Diabetes, oxidative stress, and
antioxidants: a review. J Biochem Mol Toxicol 2003, 17:24–38.
9. Hayat SA, PATEL B, Khattar RS, MALIK RA: Diabetic cardiomyopathy:
mechanisms, diagnosis and treatment. Clin Sci 2004, 107:539–557.
10. Halestrap AP, Clarke SJ, Javadov SA: Mitochondrial permeability transition
pore opening during myocardial reperfusion- a target for cardioprotection.
Cardiovasc Res 2004, 61:372–385.
11. Crompton M: The mitochondrial permeability transition pore and its role
in cell death. Biochem J 1999, 341(2):233–249.
12. Gateau-Roesch O, Argaud L, Ovize M: Mitochondrial permeability transition
pore and postconditioning. Cardiovasc Res 2006, 70:264–273.
13. Huhn R, Heinen A, Hollmann MW, Schlack W, Preckel B, Weber NC:
Cyclosporine A administered during reperfusion fails to restore
cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab
Cardiovasc Dis 2009, 20:706–712.
14. Ebel D, Toma O, Appler S, Baumann K, Frabdorf J, Preckel B, Rosen P,
Schlack W, Weber NC: Ischemic preconditioning phosphorylates
mitogena ctivated kinases and heat shock protein 27 in the
diabetic rat heart. Horm Metab Res 2009, 41:10–15.
15. Ravingerova T, Stetka R, Volkovova K, Pancza D, Dzurba A, Ziegelhöffer A,
Styk J: Acute diabetes modulates response to ischemia in isolated rat
heart. Mol Cell Biochem 2000, 210:143–151.
16. Neng-Xin F, Yun-Tai Y, Chun-Xia S, Li-Huan L: Attenuation of ischemia–
reperfusion injury by sevoflurane postconditioning involves protein
kinase B and glycogen synthase kinase 3 beta activation in isolated
rat hearts. Mol Biol Rep 2010, 37:3763–3769.
17. Garjani A, Afrooziyan A, Nazemiyeh H, Najafi M, Kharazmkia A, Maleki-Dizaji N:
Protective effects of hydroalcoholic extract from rhizomes of Cynodon
Najafi et al. Journal of Diabetes & Metabolic Disorders 2014, 13:106 Page 10 of 10
http://www.jdmdonline.com/content/13/1/106dactylon (L.) Pers. on compensated right heart failure in rats. BMC
Complement Altern Med 2009, 9:28.
18. Najafi M, Garjani A, Maleki N, Eteraf-Oskouei T: Antiarrhythmic and
arrhythmogenic effects of L-carnitine in ischemia and reperfusion. B Exp
Biol Med 2008, 146(2):210–213.
19. Perrelli MG, Pagliaro P, Penna C: Ischemia/reperfusion injury and
cardioprotective mechanisms: role of mitochondria and reactive oxygen
species. World J Cardiol 2011, 3(6):186–200.
20. Kobayashi T, Taguchi K, Yasuhiro T, Matsumoto T, Kamata K: Impairment of
PI3-K/Akt pathway underlies attenuated endothelial function in aorta of
type 2 diabetic mouse model. Hypertension 2004, 44:956–962.
21. Rasola A, Sciacovelli M, Pantic B, Bernardi P: Signal transduction to the
permeability transition pore. FEBS Lett 2010, 584:1989–1996.
22. Zorov DB, Juhaszova M, Yaniv Y, Nuss HB, Wang S, Sollott SJ: Regulation
and pharmacology of the mitochondrial permeability transition pore.
Cardiovasc Res 2009, 83:213–225.
23. Azarashvili T, Odinokova I, Bakunts A, Ternovsky V, Krestinina O, Tyynelä J,
Saris NL: Potential role of subunit c of F0/F1-ATPase and subunit c of
storage body in the mitochondrial permeability transition. Effect of the
phosphorylation status of subunit c on pore opening. Cell Calcium 2014,
55(2):69–77.
24. Bonora M, Wieckowski MR, Chinopoulos C, Kepp O, Kroemer G, Galluzzi L,
Pinton P: Molecular mechanisms of cell death: central implication of ATP
synthase in mitochondrial permeability transition. Oncogene 2014, 1–12.
doi:10.1038/onc.2014.96.
25. Alavian KN, Beutner G, Lazrove E, Sacchetti S, Park HA, Licznerski P, Li H,
Nabili P, Hockensmith K, Graham M, Porter GA, Jonas EA: An uncoupling
channel within the c-subunit ring of the F1FO ATP synthase is the
mitochondrial permeability transition pore. Proc Natl Acad Sci USA
2014, 111(29):10580–10585.
26. Bonora M, Bononi A, De Marchi E, Giorgi C, Lebiedzinska M, Marchi S,
Patergnani S, Rimessi A, Suski JM, Wojtala A, Wieckowski MR, Kroemer G,
Galluzzi L, Pinton P: Role of the c subunit of the FO ATP synthase in
mitochondrial permeability transition. Cell Cycle 2013, 12(4):674–683.
27. Wagner C, Kloeting I, Strasser RH, Weinbrenner C: Cardioprotection by
postconditioning is lost in WOKW rats with metabolic syndrome: role of
glycogen synthase kinase 3b. J Cardiovasc Pharmacol 2008, 52:430–437.
28. Przyklenk K, Maynard M, Greiner DL, Whittaker P: Cardioprotection with
postconditioning: loss of efficacy in murine models of type-2 and type-1
diabetes. Antioxid Redox Signal 2011, 14:781–790.
29. An D, Rodrigues B: Role of changes in cardiac metabolism in development of
diabetic cardiomyopathy. AJP 2006, 291(4):H1489–H1506.
doi:10.1186/s40200-014-0106-1
Cite this article as: Najafi et al.: Inhibition of mitochondrial permeability
transition pore restores the cardioprotection by postconditioning in
diabetic hearts. Journal of Diabetes & Metabolic Disorders 2014 13:106.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
